Back to Cell Types

LK-2Homo sapiens (Human)Cancer cell line

Also known as: LK2, LK 2

🤖 AI SummaryBased on 13 publications

Quick Overview

LK-2 is a human lung cancer cell line used in cancer research.

Detailed Summary

LK-2 is a human lung cancer cell line that has been utilized in various cancer research studies. It is known for its role in investigating genetic mutations and their implications in cancer progression. The cell line has been part of studies focusing on the EGFR gene and its mutations, which are significant in the development of targeted therapies. Additionally, LK-2 has been used in research related to the identification of tumor suppressor genes and their inactivation mechanisms. The cell line's characteristics make it a valuable tool for understanding the molecular basis of lung cancer and developing effective treatment strategies.

Generated on 6/16/2025

Basic Information

Database ID	CVCL_1377
Species	Homo sapiens (Human)
Tissue Source	Lung[UBERON:UBERON_0002048]

Donor Information

Age	74
Age Category	Adult
Sex	Male

Disease Information

Disease	Lung squamous cell carcinoma
Lineage	Lung
Subtype	Lung Squamous Cell Carcinoma
OncoTree Code	LUSC

DepMap Information

Source Type	RIKEN
Source ID	ACH-000769_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Val272Met (c.814G>A)	Unspecified	-	from parent cell line TE-1
MutationSimple	CDKN2A	p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T)	Homozygous	-	from parent cell line DU145
MutationSimple	APC	p.Trp685Ter (c.2055G>A)	Homozygous	-	Unknown, Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

9

D13S317

8

D16S539

9

D5S818

12

D7S820

8

TH01

6

TPOX

9

vWA

16,17

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Genetic diversity among the present Japanese population: evidence from genotyping of human cell lines established in Japan.

Kasai F., Fukushima M., Miyagi Y., Nakamura Y.

Hum. Cell 37:944-950(2024).

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

Gene-expression data integration to squamous cell lung cancer subtypes reveals drug sensitivity.

Wu D., Pang Y., Wilkerson M.D., Wang D., Hammerman P.S., Liu J.S.

Br. J. Cancer 109:1599-1608(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.

Igishi T., Burioka N., Nanba E., Shimizu E.

Cancer Biol. Ther. 13:369-378(2012).

Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.

Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.

Cancer Sci. 101:1891-1896(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

A gene-alteration profile of human lung cancer cell lines.";

Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

Hum. Mutat. 30:1199-1206(2009).

Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.

Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., Hagiwara K.

Cancer Res. 65:7276-7282(2005).

Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers.

Hirohashi S., Inazawa J., Imoto I.

Hum. Mol. Genet. 14:997-1007(2005).

TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers.

Yokoi S., Yasui K., Iizasa T., Imoto I., Fujisawa T., Inazawa J.

Clin. Cancer Res. 9:4705-4713(2003).

Establishment of a drug sensitivity panel using human lung cancer cell lines.

Kohara H., Harada M.

Acta Med. Okayama 53:67-75(1999).

Screening the p53 status of human cell lines using a yeast functional assay.

Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Mol. Carcinog. 19:243-253(1997).